Pacer Advisors’s Prelude Therapeutics PRLD Stock Holding History

Pacer Advisors’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,126	Closed	-$49K	–	1515
2021 Q1	$49K	Buy	+1,126	New	+$74.7K	﹤0.01%	1441

Other funds holding PRLD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Pacer Advisors's PRLD Position: Q2 2021 in Review

Pacer Advisors sold out of Prelude Therapeutics (PRLD) in Q2 2021, closing a stake of 1,126 shares — an estimated $49K sold.

Pacer Advisors first reported a position in PRLD in Q1 2021 and held it in 1 quarter. The position peaked at $49K in Q1 2021. 57 funds tracked by Wall St. Rank hold PRLD as of Q2 2021.

Pacer Advisors reported no remaining Prelude Therapeutics position as of Q2 2021 after selling out during the quarter.
Pacer Advisors sold 1,126 Prelude Therapeutics shares in Q2 2021, an estimated $49K.
Pacer Advisors first reported a position in Prelude Therapeutics in Q1 2021 and held it in 1 quarter.
Pacer Advisors's Prelude Therapeutics position peaked at $49K in Q1 2021.
57 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2021.

Based on Pacer Advisors's 13F filing for Q2 2021, filed 21 Jul 2021.